Document Classification

Section Type: RESULTS

Text: In the two groups, the level of ET [(78 + / - 8) and (69 + / - 5) ng/L], TXB (2) [(87 + / - 13) and (73 + / - 8) ng/L], ET/NO [(26. 7 + / - 1. 5) x 10 (3) and (21. 8 + / - 1. 1) x 10 (3)], TXB (2) / 6-Keto-PGF (1a) (0. 84 + / - 0. 36 and 0. 58 + / - 0. 11, clinical symptom score 2. 4 + / - 1. 6 and 1. 8 + / - 1. 3) after treatment were decreased significantly as compared to the levels of ET [(83 + / - 8) and (84 + / - 4) ng/L], TXB (2) [(102 + / - 16) and (103 + / - 13) ng/L], ET/NO [(35. 0 + / - 2. 7) x 10 (3) and (36. 3 + / - 3. 1) x 10 (3)], TXB (2) / 6-Keto-PGF (1a) (1. 28 + / - 0. 38 and 1. 24 + / - 0. 28), clinical symptom score (4. 4 + / - 2. 3 and 4. 4 + / - 2. 0) before treatment.